Cargando…
Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study
Autores principales: | Yen, Chieh-Li, Wu, Chao-Yi, See, Lai-Chu, Li, Yi-Jung, Tseng, Min-Hua, Peng, Wei-Sheng, Liu, Jia-Rou, Chen, Yung-Chang, Yen, Tzung-Hai, Tian, Ya-Chung, Yang, Chih-Wei, Anderson, Gerard F., Yang, Huang-Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510024/ https://www.ncbi.nlm.nih.gov/pubmed/32801131 http://dx.doi.org/10.2337/dc20-1584 |
Ejemplares similares
-
Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006–2016
por: Lin, Min-Hao, et al.
Publicado: (2020) -
Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study
por: Yen, Chieh-Li, et al.
Publicado: (2023) -
Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting
por: Wang, Tiansheng, et al.
Publicado: (2019) -
Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System
por: Wang, Tiansheng, et al.
Publicado: (2019) -
Pioglitazone-Induced Acute Rhabdomyolysis
por: Slim, Raoudha, et al.
Publicado: (2009)